Navigation Links
China-Biotics, Inc. Reports Second Quarter 2009 Financial Results

SHANGHAI, China, Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for the second quarter of its 2009 fiscal year, ended September 30, 2008.

Second Quarter 2009 Highlights

-- Net sales increased 47.0% year-over-year to $11.5 million

-- Gross profit increased 43.1% year-over-year to $8.0 million

-- Gross margin was 69.9%

-- Net income was $4.5 million

-- Excluding a $1.9 million gain related to the change in fair value of

convertible notes, net income increased 30.4% year over year to $2.6


-- Diluted earnings per share was $0.13, compared to $0.11 the prior year

-- Opened 27 retail outlets during the quarter, bringing the total number

of outlets to 110 in 13 cities in China

-- Signed agreement with Henan Square Pharmaceutical Co., Ltd to supply

probiotics for its probiotics-based medicines

-- Began installing equipment for its new manufacturing facility in Qing

Pu Industrial Park in Shanghai

-- Began trading on the Nasdaq Global Market in October

Second Quarter 2009 Results

During the second quarter of the 2009 fiscal year, net sales increased 47.0% to $11.5 million from $7.8 million the prior year, as a result of growth in the sales volume of new products and increases in the sales price of selected products. Sales also benefited from an increase in the number of the Company's Shining retail outlets to 110 from 22 the prior year. New products, including Shining Essence Stomach Protection Capsules, Shining Probiotics Protein Powder and other products accounted for 16.3% of total sales during the quarter, up from a combined 4.0% a year ago. Sales of bulk additives to commercial customers totaled $1.4 million, or 12.2% of sales, during the second quarter of 2009, up from $1.0 million, or 8.8% of sales, during the fiscal first quarter. There were no bulk additives sales in the second quarter the prior year.

"We are delighted to see continued revenue growth in the second quarter, as we benefited from strong volume and price increases in our retail business and increased demand from our existing bulk additives customers," said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "Our Shining retail outlet expansion resulted in an additional 27 openings during the quarter and should result in increased profits during the second half of the fiscal year. As we prepare for the completion of our new manufacturing facility, we are carefully balancing existing production capacity between our retail expansion and bulk additive business development. We signed one new bulk customer during the second quarter, and we remain in negotiations with more than 100 potential business clients."

Gross profit during the quarter increased 43.1% to $8.0 million from $5.6 million in the second quarter the prior year. Gross margin was 69.9%, compared to 71.8% a year ago. This was primarily caused by an increase in the price of electricity used to run the Company's manufacturing facility and an increase in the cost of packaging materials, including pulp and paper costs.

Selling expenses increased to $2.8 million, or 24.5% of sales, from $1.6 million, or 20.0% of sales, in the second quarter a year ago, as the Company significantly increased the number of retail outlets. General and administrative expenses increased to $1.4 million, or 12.5% of sales, from $1.1 million, or 13.9% of sales, in the second quarter of fiscal 2008. The increase was primarily related to $0.3 million of additional research costs to develop and launch new products and staff and administrative costs incurred in connection with the construction of the new manufacturing facility. As of September 30, 2008, the Company had 339 employees and operated 110 Shining- branded retail outlets, up from 266 employees and 22 Shining outlets on September 30, 2007.

Operating expenses during the quarter were $4.3 million, or 37.0% of sales, compared to $2.6 million, or 33.9% of sales, a year ago.

Operating income for the quarter was $3.8 million, compared to $3.0 million a year ago.

Other income of $2.0 million in the second quarter of 2009 consisted of a $1.9 million book gain related to the change in the fair value of the $25 million convertible notes issued in December 2007.

Net income for the second quarter was $4.5 million. Excluding the $1.9 million gain on the revaluation of the convertible notes, net income was $2.6 million, up 30.4% from $2.0 million during the same quarter a year ago.

Diluted earnings per share were $0.13, calculated on a weighted average basis, compared with $0.11 per diluted share in the second quarter of fiscal 2008. The calculation of diluted earnings per share for the second quarter of 2009 assumes full conversion of the convertible notes and thus excludes the gain from the change in fair value of the notes.

Six Month Results

Net sales for the first six months of fiscal 2009 were $22.9 million, up 31.9% from $17.3 million in the same period the prior year. Gross profit was $16.1 million, or 70.6% of sales, up 29.4% from gross profit of $12.5 million, or 72.0% of sales, in the first half of fiscal 2008. Operating income was $8.1 million, or 35.4% of sales, up 5.1% from operating income of $7.7 million, or 44.4% of sales, the prior year. Net income for the first six months of fiscal 2009 was $7.7 million, or $0.37 per diluted share, up from $5.5 million, or $0.32 per diluted share, in the same period of fiscal 2008.

Financial Condition

As of September 30, 2008, the Company had cash and cash equivalents of $65.6 million and working capital of $49.2 million. We were able to slightly increase our cash balance despite having $11.7 million of capital expenditures during the first six months of 2009. Days' sales outstanding for the second quarter of the 2009 fiscal year was 85 days. At September 30, 2008, the Company had stockholders' equity of $53.1 million.

In the first six months of 2009, China-Biotics generated $12.7 million in cash flow from operations and recorded $11.7 million in capital expenditures mainly related to the construction of its new $27.5 million manufacturing facility, $25 million of which is to be paid by the end of the third quarter of fiscal 2009. The remaining balance is expected to be paid during fiscal 2010. The Company believes its current cash balance, combined with cash flow from operations, will be sufficient to fund its planned expenditures during the next 12 months.

Business Outlook

The Company's new bulk additives production facility remains scheduled to begin production during the fiscal third quarter. As of September 30, 2008, China-Biotics had signed contracts with five business customers to supply those customers with bulk probiotics in powder form that can be added to products such as milk, ice cream, yogurt, baked goods and nutritional supplements. The Company was in discussions with more than 100 other potential customers in that segment in preparation for the plant coming online at the end of this calendar year.

With limited capacity in its existing production facility, management believes it is prudent to proceed with the retail outlet expansion at a measured pace, which will enable the Company to focus on the completion of the new manufacturing facility and signing on customers to fill production capacity once the new facility becomes operational. As a result, the Company's plan to open a total of 300 Shining retail outlets is expected to be completed in the 2010 fiscal year.

"As we look to the second half of the year, we continue to make great progress in our retail expansion strategy, and we expect that our new manufacturing facility will come online during the fiscal third quarter," Mr. Song said. "We now have 22 Shining outlets that have been open at least one year, and all of these have demonstrated very strong growth year-over-year. As we accelerate our rollout of Shining outlets, we expect a significant increase in selling expenses. However, sales from existing outlets should help to offset increased expenses, as 60% of our retail sales typically occur during the second half of our fiscal year. The bulk additive business should continue to expand, as our new facility becomes operational and we are able to take on additional orders."

Recent Events

In October 2008, the Company announced it was approved to list shares of its common stock on the Nasdaq Global market. Shares began trading on Nasdaq on October 23 under the symbol "CHBT."

Also in October 2008, the Company announced that it has engaged the Shanghai office of KPMG Advisory (China) Limited to assist the Company in complying with the financial reporting and controls requirements of Sarbanes- Oxley Act Section 404 ("SOX 404"). KPMG Shanghai's engagement is designed to assist China-Biotics as it complies with SOX 404, which requires the Company and its external auditor to report on the adequacy of the Company's internal financial reporting and controls systems after documenting and testing financial reporting and control procedures.

Conference Call

The company will host a conference call at 9:00 a.m. EST on, Tuesday, November 11, 2008, to discuss its financial results for the fiscal second quarter ended September 30, 2008. To participate in the event by telephone, please dial 888-241-0558 five to 10 minutes prior to the start time (to allow time for registration) and reference passcode 71784337. International callers should dial 647-427-3417. The conference call will be broadcast live over the Internet and can be accessed by all interested parties atthe Company's Web site, . To listen to the call, please visit the site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. For those unable to participate during the live webcast, it will be archived using the same link for 90 days. A digital replay of the call will also be available on Tuesday, November 11, at approximately 11:00 a.m. EST through Tuesday, November 18, at midnight EST. Dial 800-677-6425 and enter the conference ID number 71784337. International callers should dial 402-220-1449 and enter the same conference ID number.

Use of Non-GAAP Financial Information

GAAP results for the second quarter ended September 30, 2008, include a non-cash gain related to the change in fair value of the Company's convertible notes. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item, which is non-GAAP net income, in this release. The Company's management believes that this non-GAAP measure provides investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.




(Amounts expressed in US Dollars)

September 30, March 31,

2008 2008

ASSETS (unaudited)

Current assets

Cash and cash equivalents $65,633,495 $64,310,448

Accounts receivable 10,447,251 13,214,531

Other receivables 243,497 238,835

Inventories 765,640 408,358

Prepayment 1,828,612 1,806,605

Total current assets $78,918,495 $79,978,777

Property, plant and equipment

and land use right 27,309,641 13,812,749

Total assets $106,228,136 $93,791,526


Current liabilities

Accounts payable $3,448,485 $2,786,180

Tax payables 24,094,685 22,317,982

Other payables and accruals 2,127,050 1,792,156

Total current liabilities $29,670,220 $26,896,318

Non-current liabilities

Convertible note, with embedded

derivatives of $5,087,000, net

of discount of $7,341,762 as of

September 30, 2008 $22,745,238 $22,197,635

Interest payable 740,628 302,306

Total non-current liabilities $23,485,866 $22,499,941

Commitments and contingencies

Stockholders' equity:

Common stock (par value of $0.0001,

100,000,000 shares authorized,

41,461,004 shares issued and

outstanding as of September 30, 2008) $4,146 $4,146

Additional paid-in capital 7,863,031 7,863,031

Retained earnings 37,536,014 29,827,144

Treasury stock at cost

(24,381,004 shares) (2,438) (2,438)

Accumulated other comprehensive

income 4,645,503 3,677,590

Capital and statutory reserves 3,025,794 3,025,794

Total stockholders' equity $53,072,050 $44,395,267

Total liabilities and stockholders'

equity $106,228,136 $93,791,526



(Amounts expressed in U.S. Dollars)

Three months ended Six months ended

September 30, September 30,

2008 2007 2008 2007

Net sales $11,495,249 $7,820,163 $22,865,906 $17,335,496

Cost of sales (3,462,853) (2,205,623) (6,721,522) (4,856,595)

Gross profit $8,032,396 $5,614,540 $16,144,384 $12,478,901

Operating expenses:

Selling expenses $(2,813,563) $(1,561,936) $(5,183,422) $(2,878,280)

General and


expenses (1,438,137) (1,087,053) (2,864,933) (1,896,617)

Total operating

expenses $(4,251,700) $(2,648,989) $(8,048,355) $(4,774,897)

Income from operations $3,780,696 $2,965,551 $8,096,029 $7,704,004

Other income and


Changes in the fair

value of embedded

derivatives $1,904,000 $-- $665,000 $--

Other income 157,468 282 1,862,988 71,942

Other expenses (50,947) (13,011) (217,579) (19,935)

Total other income

(expenses) $2,010,521 $(12,729) $2,310,409 $52,007

Income before taxes $5,791,217 $2,952,822 $10,406,438 $7,756,011

Provision for income

taxes (1,319,097) (982,689) (2,697,568) (2,245,645)

Net income $4,472,120 $1,970,133 $7,708,870 $5,510,366

Earnings per share:

Basic $0.26 $0.11 $0.45 $0.32

Diluted $0.13 $0.11 $0.37 $0.32

Weighted average

shares outstanding:

Basic 17,080,000 17,080,000 17,080,000 17,080,000

Diluted 19,163,333 17,080,000 19,163,333 17,080,000



(Amounts expressed in US Dollars)

Six months ended

September 30,

2008 2007


Net income $7,708,870 $5,510,366

Adjustment for:

Changes in the fair value of embedded

derivatives (665,000) --

Depreciation 863,740 349,111

(Increase)/Decrease in accounts

receivable 3,044,946 5,992,036

(Increase)/Decrease in inventories (344,093) (383,380)

(Increase)/Decrease in prepayments 19,822 (1,693,248)

Increase/(Decrease) in accounts

payable 586,894 239,274

Increase/(Decrease) in income tax,

surcharge tax and dividends

withholding tax 1,249,548 828,172

Increase/(Decrease) in other payables

and accruals, and value added tax

payable 205,230 348,841


ACTIVITIES $12,669,957 $11,191,172



Purchases of fixed assets $(11,662,222) $(4,027,160)


Interest paid $(556,164) $--

Effect of exchange rate changes on

cash $871,476 $1,065,937


EQUIVALENTS BALANCES $1,323,047 $8,229,949


BEGINNING OF PERIOD 64,310,448 26,992,025


END OF PERIOD $65,633,495 $35,221,974



Three months Three months

ended ended

September 30, September 30,

Non-GAAP Net income 2008 2007

Net Income (Loss) $2,568,120 $1,970,133


Non-cash gain from change in fair

value of embedded derivatives 1,904,000 --

Amount per consolidated statement of

operations $4,472,120 $1,970,133

Six months Three months

ended ended

September 30, September 30,

Non-GAAP Net income 2008 2007

Net Income (Loss) $7,043,870 $5,510,366


Non-cash gain from change in fair

value of embedded derivatives 665,000 --

Amount per consolidated statement of

operations $7,708,870 $5,510,366

For more information, please contact:

CCG Investor Relations

Crocker Coulson, President

Tel: +1-646-213-1915 (New York)



SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
5. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
6. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. China-Biotics, Inc. Completes Foundation for Its New Plant
9. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
10. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
11. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader ... five states to develop and pitch their BIG ideas to improve health and wellness ... competing for votes to win the title of SAP's Teen Innovator, an all-expenses paid ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" ... , President and Chief Executive Officer of ProMetic, will be ... th Annual Healthcare Conference to be held at the ... st , at 8.50am (ET) and ProMetic,s management team ... presentation will be available live via a webcast accessible at ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
Breaking Biology News(10 mins):